All In Biotech

Drug Trial Radar · NCT03591068

Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video

A 24-Week Open-Label Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day (BID) in Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video

Last checked: Nov 19, 2026Latest source record: Aug 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

11

Actual

Start

Jun 7, 2018

Primary completion

Feb 22, 2019

Study completion Feb 22, 2019

Sponsor

Lead sponsor
Optinose US Inc.Industry
Sponsor type
Industry
First posted
Jul 18, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 24-week, open-label, multi-center study designed to assess the efficacy and safety of OPN-375 186 μg twice a day in subjects with nasal polyps using Nasoendoscopic video. The total planned number of subjects is approximately 10, with each subject receiving OPN-375 186 μg twice a day.

Conditions

  • Nasal Polyposis

Interventions

  • Fluticasone PropionateDrug

    OPN-375 186 μg BID, Delivered via exhalation delivery system

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Visit 1 at End of Study in Bilateral Nasal Polyp Grade Using Endoscopic VideoTime frame: Week 24

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University of Colorado SOM, Department of Otolaryngology

    Aurora, Colorado

  • University of Texas Health Science Center at Houston, McGovern Medical School, Dept. of Otolaryngology, Head and Neck Surgery

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.